$BOLT
Bolt Biotherapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024487 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $1.411M $2.112M $800.0K
YoY Change 177.76% 164.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.606M $5.485M $4.941M
YoY Change 9.94% 11.01% 72.16%
% of Gross Profit
Research & Development $16.85M $18.97M $19.34M
YoY Change -25.08% -1.88% 102.69%
% of Gross Profit
Depreciation & Amortization $462.0K $400.0K $304.0K
YoY Change 27.98% 31.58% 52.0%
% of Gross Profit
Operating Expenses $22.45M $24.46M $24.28M
YoY Change -18.61% 0.74% 95.63%
Operating Profit -$22.35M -$23.53M
YoY Change -5.02%
Interest Expense $1.043M $587.0K $131.0K
YoY Change -1371.95% 348.09% 555.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $587.0K $0.00
YoY Change -100.0%
Pretax Income -$20.00M -$21.76M -$23.40M
YoY Change -26.37% -6.99% 133.95%
Income Tax
% Of Pretax Income
Net Earnings -$20.00M -$21.76M -$23.40M
YoY Change -26.37% -6.99% 133.93%
Net Earnings / Revenue -1417.22% -1030.26% -2924.38%
Basic Earnings Per Share -$0.58 -$0.63
Diluted Earnings Per Share -$0.53 -$0.58 -$628.8K
COMMON SHARES
Basic Shares Outstanding 37.66M 37.64M 37.21M
Diluted Shares Outstanding 37.45M 37.21M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $168.9M $171.1M $212.9M
YoY Change -9.31% -19.62% 464.7%
Cash & Equivalents $9.244M $10.62M $23.65M
Short-Term Investments $159.6M $160.5M $189.2M
Other Short-Term Assets $3.858M $3.696M $9.595M
YoY Change 31.18% -61.48% 405.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $172.7M $174.8M $222.5M
YoY Change -8.68% -21.42% 460.42%
LONG-TERM ASSETS
Property, Plant & Equipment $6.453M $6.905M $5.631M
YoY Change 4.79% 22.62% -67.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $23.94M $38.43M $77.64M
YoY Change -71.95% -50.5%
Other Assets $1.028M $1.000M $2.555M
YoY Change -1.34% -60.86% -48.9%
Total Long-Term Assets $55.06M $70.68M $111.1M
YoY Change -53.56% -36.36% 404.83%
TOTAL ASSETS
Total Short-Term Assets $172.7M $174.8M $222.5M
Total Long-Term Assets $55.06M $70.68M $111.1M
Total Assets $227.8M $245.5M $333.6M
YoY Change -25.97% -26.4% 440.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.594M $3.828M $5.155M
YoY Change 0.56% -25.74% 51.62%
Accrued Expenses $17.53M $17.18M $13.33M
YoY Change 17.78% 28.83% 166.66%
Deferred Revenue $1.400M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.12M $24.17M $23.70M
YoY Change 8.39% 2.02% 139.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $42.00K $200.0K $34.94M
YoY Change -80.0% -99.43% 65.6%
Total Long-Term Liabilities $42.00K $200.0K $34.94M
YoY Change -80.0% -99.43% 65.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.12M $24.17M $23.70M
Total Long-Term Liabilities $42.00K $200.0K $34.94M
Total Liabilities $56.30M $57.06M $58.64M
YoY Change -2.25% -2.69% 89.15%
SHAREHOLDERS EQUITY
Retained Earnings -$295.1M -$275.1M
YoY Change 42.57%
Common Stock $467.5M $465.2M
YoY Change 2.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $171.5M $188.4M $274.9M
YoY Change
Total Liabilities & Shareholders Equity $227.8M $245.5M $333.6M
YoY Change -25.97% -26.4% 440.6%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$20.00M -$21.76M -$23.40M
YoY Change -26.37% -6.99% 133.93%
Depreciation, Depletion And Amortization $462.0K $400.0K $304.0K
YoY Change 27.98% 31.58% 52.0%
Cash From Operating Activities -$17.95M -$13.45M -$18.73M
YoY Change 0.89% -28.17% 49.58%
INVESTING ACTIVITIES
Capital Expenditures $184.0K -$735.0K -$1.015M
YoY Change -132.74% -27.59% -11.74%
Acquisitions
YoY Change
Other Investing Activities $16.62M $2.185M -$15.10M
YoY Change -23.04% -114.47% 26.43%
Cash From Investing Activities $16.44M $1.450M -$16.11M
YoY Change -21.86% -109.0% 22.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 144.0K 0.000 185.0K
YoY Change -70.91% -100.0% -119.89%
NET CHANGE
Cash From Operating Activities -17.95M -13.45M -18.73M
Cash From Investing Activities 16.44M 1.450M -16.11M
Cash From Financing Activities 144.0K 0.000 185.0K
Net Change In Cash -1.373M -12.00M -34.65M
YoY Change -136.77% -65.37% 30.52%
FREE CASH FLOW
Cash From Operating Activities -$17.95M -$13.45M -$18.73M
Capital Expenditures $184.0K -$735.0K -$1.015M
Free Cash Flow -$18.14M -$12.72M -$17.71M
YoY Change 5.25% -28.21% 55.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6358000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-38000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
713000
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001641281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39988
dei Entity Registrant Name
EntityRegistrantName
Bolt Biotherapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2804636
dei Entity Address Address Line1
EntityAddressAddressLine1
900 Chesapeake
dei Entity Address Address Line2
EntityAddressAddressLine2
Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei Entity Small Business
EntitySmallBusiness
true
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
665-9295
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
dei Trading Symbol
TradingSymbol
BOLT
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24445000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7187000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
189160000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6905000
us-gaap Investment Income Net
InvestmentIncomeNet
1180000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6158000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22777000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37660893
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10617000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27383000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
160513000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
158836000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3696000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2941000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
174826000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1565000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1565000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
38432000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
85348000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1042000
CY2022Q3 us-gaap Assets
Assets
245505000
CY2021Q4 us-gaap Assets
Assets
307718000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3828000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3574000
CY2022Q3 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14793000
CY2021Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12384000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3169000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2869000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2384000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2501000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24174000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21328000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20857000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21854000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11828000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14207000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
200000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
210000
CY2022Q3 us-gaap Liabilities
Liabilities
57059000
CY2021Q4 us-gaap Liabilities
Liabilities
57599000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
us-gaap Investment Income Net
InvestmentIncomeNet
363000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2481000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7225000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37399694
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37660893
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37660893
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37399694
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
465246000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457430000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1709000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-321000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275091000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206990000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
188446000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250119000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
245505000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
307718000
CY2022Q3 us-gaap Revenues
Revenues
2112000
CY2021Q3 us-gaap Revenues
Revenues
752000
us-gaap Revenues
Revenues
4318000
us-gaap Revenues
Revenues
752000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18973000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19337000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56278000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53171000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5485000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4941000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17321000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13294000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
24458000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
24278000
us-gaap Operating Expenses
OperatingExpenses
73599000
us-gaap Operating Expenses
OperatingExpenses
66465000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22346000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23526000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69281000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65713000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
587000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
131000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000
bolt Change In Fair Value Of Convertible Preferred Stock Purchase Rights Liabilities
ChangeInFairValueOfConvertiblePreferredStockPurchaseRightsLiabilities
6084000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
587000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
131000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1180000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5721000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21759000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-23395000
us-gaap Net Income Loss
NetIncomeLoss
-68101000
us-gaap Net Income Loss
NetIncomeLoss
-71434000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
94000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1388000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-38000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21665000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23410000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69489000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71472000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37454340
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37454340
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37206793
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37206793
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37293121
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37293121
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31824180
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31824180
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
207968000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2143000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
94000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21759000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
188446000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
295896000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
185000
CY2021Q3 bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
16000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2226000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-23395000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
274913000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250119000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
4000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7453000
us-gaap Net Income Loss
NetIncomeLoss
-71434000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
274913000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1388000
us-gaap Net Income Loss
NetIncomeLoss
-68101000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
188446000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-104947000
us-gaap Profit Loss
ProfitLoss
-68101000
us-gaap Profit Loss
ProfitLoss
-71434000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1204000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
832000
us-gaap Share Based Compensation
ShareBasedCompensation
7453000
us-gaap Share Based Compensation
ShareBasedCompensation
6358000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
188506000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
241959000
bolt Issuance Of Common Stock Related To Stock Purchase Agreement
IssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-655000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1833000
bolt Change In Fair Value Of Convertible Preferred Stock Purchase Rights Liabilities
ChangeInFairValueOfConvertiblePreferredStockPurchaseRightsLiabilities
6084000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2520000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1935000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
337000
bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
114000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1966000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-831000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2079000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
15911000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58552000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39272000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1769000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1776000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
155345000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
283688000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
198541000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32230000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
41427000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-253234000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
51902000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
244316000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
359000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
757000
bolt Proceeds From Issuance Of Common Stock Related To Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
359000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
310613000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16766000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18107000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28948000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7107000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12182000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25214000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10617000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23649000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12182000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25214000
bolt Vesting Of Exercised Options
VestingOfExercisedOptions
4000
bolt Vesting Of Exercised Options
VestingOfExercisedOptions
114000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
182000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
591000
bolt Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
102000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
852000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14884000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
209600000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, stock-based compensation and accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. As of September 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, most of the Company’s funds were invested with a registered investment manager and custodied at one financial institution, with operating cash kept at a separate financial institution, and account balances may at times exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions where the funds are held.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1600000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1600000
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
200654000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1709000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
198945000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
244505000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
333000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4093000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
244184000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10358000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8403000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3453000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2245000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6905000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6158000
CY2022Q3 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
1200000
CY2021Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
800000
CY2022Q3 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
9333000
CY2021Q4 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6300000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4886000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1367000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1198000
CY2022Q3 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14793000
CY2021Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12384000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.107
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1051000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1229000
us-gaap Operating Lease Cost
OperatingLeaseCost
3226000
us-gaap Operating Lease Cost
OperatingLeaseCost
2721000
us-gaap Operating Lease Payments
OperatingLeasePayments
3413000
us-gaap Operating Lease Payments
OperatingLeasePayments
1884000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1247000
CY2022Q3 bolt Lessee Operating Sublease Income Receivable Remainder Of Fiscal Year
LesseeOperatingSubleaseIncomeReceivableRemainderOfFiscalYear
171000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4726000
CY2022Q3 bolt Lessee Operating Sublease Income Due Next Twelve Months
LesseeOperatingSubleaseIncomeDueNextTwelveMonths
699000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4886000
CY2022Q3 bolt Lessee Operating Sublease Income Due Year Two
LesseeOperatingSubleaseIncomeDueYearTwo
540000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4340000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3484000
CY2022Q3 bolt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16840000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
35523000
CY2022Q3 bolt Lessee Operating Sublease Income
LesseeOperatingSubleaseIncome
1410000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12282000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23241000
us-gaap Sublease Income
SubleaseIncome
1410000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2143000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2226000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7453000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6358000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21759000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-23395000
us-gaap Net Income Loss
NetIncomeLoss
-68101000
us-gaap Net Income Loss
NetIncomeLoss
-71434000
CY2022Q3 bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37645895
CY2021Q3 bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37214513
bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37533016
bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
31837227
CY2022Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
191555
CY2021Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
7720
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
239895
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
24847
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
11800
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37454340
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37454340
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37206793
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37206793
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37293121
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37293121
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31824180
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31824180
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7418968
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5202241

Files In Submission

Name View Source Status
0000950170-22-024487-index-headers.html Edgar Link pending
0000950170-22-024487-index.html Edgar Link pending
0000950170-22-024487.txt Edgar Link pending
0000950170-22-024487-xbrl.zip Edgar Link pending
bolt-20220930.htm Edgar Link pending
bolt-20220930.xsd Edgar Link pending
bolt-ex31_1.htm Edgar Link pending
bolt-ex31_2.htm Edgar Link pending
bolt-ex32_1.htm Edgar Link pending
bolt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
bolt-20220930_cal.xml Edgar Link unprocessable
bolt-20220930_def.xml Edgar Link unprocessable
bolt-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bolt-20220930_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bolt-20220930_pre.xml Edgar Link unprocessable